Tradestie Institutional Equity Comparison Engine

NRIX vs ACHV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ACHV Overall Edge

ACHV Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Achieve Life Sciences, Inc. (ACHV) driven by superior Valuation, Momentum & Technical, Options & Structure while NRIX counters with relative strength in Growth & Margin. Fundamentally, NRIX trades at N/M Forward P/E with 41.3% operating margin (+8426.3% YoY revenue) versus ACHV at 35.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against ACHV sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ACHV
NRIX N/M vs ACHV 35.3x Fwd P/E
Growth & Margin Winner NRIX
Op Margin 41.3% vs 0.0% ยท YoY +8426.3% vs +0.0%
Momentum & Technical Winner ACHV
1Y +19.6% vs +43.0% ยท 52W Pos 18% vs 69%
Options & Structure Winner ACHV
BREAKDOWN (4th %ile IV) vs BREAKOUT (23rd %ile IV)
NRIX NASDAQ
Nurix Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$14.87
-3.94% 1D
Market Cap $1.7B
1M Return -39.11%
1Y Return +19.63%
Forward P/E N/M
Unified AI Score
52.9 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 64.0 Mom 55.0
ACHV NASDAQ
Achieve Life Sciences, Inc.
In Vitro & In Vivo Diagnostic Substances
$6.78
+0.89% 1D
Market Cap $692.8M
1M Return -8.5%
1Y Return +43.04%
Forward P/E 35.3x
Unified AI Score
56.6 / 100 HOLD
Tech 66.0 Fund 58.0 Flow 57.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NRIX +19.63% ACHV +43.04% Spread: +18.18 pp (ACHV Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NRIX TTM Op. Margin: 41.3% ACHV TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NRIX vs ACHV. Trailing 12-month operating profitability (NRIX 41.3% vs ACHV 0.0%) and valuation multiples (NRIX N/M vs ACHV 35.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NRIX (6) vs ACHV (4)
Institutional Metric NRIX ACHV Criterion Row Winner
Market Capitalization Scale $1.7B $692.8M Larger Scale NRIX
Trailing P/E Ratio Valuation 6.4x 35.3x Lower Multiple NRIX
Forward P/E Ratio Valuation N/M 35.3x Lower Multiple ACHV
Revenue Growth (YoY) Growth +8426.3% +0.0% Higher Growth NRIX
Operating Margin (TTM) Profitability 41.3% 0.0% Higher Margin NRIX
Net Profit Margin Profitability 42.0% 0.0% Higher Margin NRIX
Return on Equity (ROE) Capital Efficiency 44.0% -845.0% Higher ROE NRIX
52-Week Range Position Momentum 18% ($12โ€“$28) 69% ($3โ€“$9) Stronger Trend ACHV
Beta / 30D Volatility Risk Regime 0.94ฮฒ ยท 141% Vol 1.73ฮฒ ยท 62% Vol Lower Realized Risk ACHV
Unified Institutional Score Composite Signal 52.9 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite ACHV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NRIX vs ACHV Buy Guide
NRIX BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live NRIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACHV BREAKOUT
125d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ACHV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NRIX nor ACHV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.